MARKET

EXEL

EXEL

Exelixis Inc
NASDAQ
65.31
+0.73
+1.13%
Pre Market: 65.31 0 0.00% 04:00 10/23 EDT
OPEN
64.74
PREV CLOSE
64.58
HIGH
65.50
LOW
64.33
VOLUME
4
TURNOVER
0
52 WEEK HIGH
65.50
52 WEEK LOW
33.76
MARKET CAP
16.18B
P/E (TTM)
20.51
1D
5D
1M
3M
1Y
5Y
1D
Exelixis Is Maintained at Market Outperform by Citizens
Dow Jones · 3d ago
Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $65
Benzinga · 3d ago
Exelixis price target raised to $65 from $55 at Citizens
TipRanks · 3d ago
Weekly Report: what happened at EXEL last week (1012-1016)?
Weekly Report · 4d ago
Exelixis (EXEL) Could Be 13% Overvalued As Pipeline Optimism Builds
Simply Wall St · 4d ago
Press Release: Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Dow Jones · 10/15 20:40
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
NASDAQ · 10/15 15:10
Weekly Report: what happened at EXEL last week (1005-1009)?
Weekly Report · 10/12 10:01
More
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Webull offers Exelixis Inc stock information, including NASDAQ: EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.